聚乙二醇干扰素α-2a联合胸腺肽α1治疗慢性乙型肝炎的效果观察

目的研究单用聚乙二醇干扰索（PEG—IFN）联合应用胸腺肽α1（Tα1）治疗慢性乙型肝炎（CHB）的效果。方法将72例CHB患者随机分为两组，分别采用单用PEG—IFN、PEG—IFN和Tα1联用两种方法治疗，疗程均为48周，比较两组患者的疗效。结果联合组治疗后的腹胀、乏力、纳差较单用组明显改善（P〈0．05），两组治疗后的肝区痛和肝脾大比较差异无统计学意义（P〉0．05）。两组治疗后24、48周的丙氨酸氨基转移酶与治疗前相比均明显下降，差异有统计学意义（P〈0．05）；联合组治疗后24、48周的丙氨酸氨基转移酶均低于单用组，差异有统计学意义（P〈0．05）。两组治疗24周病毒降低率比较差异无统计学意义（P〉0．05），两组治疗48周病毒降低率比较差异有统计学意义（P〈0．05）。联合组发热24例（66．7％），单用组发热18例（50．0％），两组比较差异无统计学意义（P=0．15）。结论PEG—IFN治疗CHB的效果确切，联合Tα1能取得更好的效果。

Effect observation of polyethylene glycol （PEG-IFN） combined with thymosin α1 （Tα1）on the treatment of chronic hepatitis B （CHB）

Obejective To study the effects of polyethylene glycol （PEG-IFN） alone and PEG-IFN combined with thymosin α1（Tα1） on the treatment of chronic hepatitis B （CHB）. Methods 72 patients with CHB were randomly divided into two groups,they were respectively used PEG-IFN alone,PEG-IFN combined with Tod two methods of treatment,the course of 48 weeks,the curative effect of two groups of patients were compared. Results The abdominal distension,lack of power,poor appetite after treatment in joint group were improved significantly than those of the alone group （P〈0.05）, the liver area pain and hepatosplenomegaly after treatment in two groups were compared,the difference had no statistical significance （P〉0.05）.The ALT after treatment 24 weeks and 48 weeks in two groups were decreased significantly than before treatment,the difference was statistically significant （P〈0.05）.The ALT after treatment 24 weeks and 48 weeks in joint group were lower than those in the alone group,the difference was statistically significant （P〈0.05）.The virus reduced rates after treatment 24 weeks between the two groups had no statistical significance （P〉0.05）,the virus reduced rates after treatment 48 weeks between the two groups had statistical significance （P〈0.05）.There were 24 cases （66.7%） fever in joint group,18 cases （50.0%） in alone group,there was no statistically significant difference in both groups （P=0.15）. Conclusion The effect of PEG-IFN treatment CHB is exactly,and it can achieve better results to combine PEG-IFN with thymosin α1.